The number of HER2-positive PID particles in breast cancer tissue analyzed from pretreatment biopsies have been shown to predict the therapeutic efficacy of the anti-HER2 antibody (trastuzumab) (21). This evidence concerns the gene ERBB2 and breast cancer.